{"id":382299,"date":"2021-02-19T11:05:04","date_gmt":"2021-02-19T14:05:04","guid":{"rendered":"https:\/\/revistapesquisa.fapesp.br\/?p=382299"},"modified":"2021-02-19T11:05:04","modified_gmt":"2021-02-19T14:05:04","slug":"antibody-treatment-reduces-time-spent-in-hospital","status":"publish","type":"post","link":"https:\/\/revistapesquisa.fapesp.br\/en\/antibody-treatment-reduces-time-spent-in-hospital\/","title":{"rendered":"Antibody treatment reduces time spent in hospital"},"content":{"rendered":"<p>On September 16, American pharmaceutical company Eli Lilly presented the initial results of a clinical trial that used monoclonal antibodies in patients infected with the novel coronavirus. The tested compound, LY-CoV555, contains antibodies against the virus, obtained in a laboratory from cloned lymphocytes that originally came from a cured COVID-19 patient. The researchers studied Ly-CoV555 in 452 volunteers with mild and moderate symptoms. Of the 302 people who received the drug, five (1.7%) required hospitalization, a figure that was 2.5 times higher among the 150 participants in the placebo group, from which 6% needed to be hospitalized. These are the first published data on the use of monoclonal antibodies against COVID-19. However, further testing is needed to determine whether the treatment is effective.<\/p>\n","protected":false},"excerpt":{"rendered":"American pharmaceutical company Eli Lilly presented the initial results of a clinical trial that used monoclonal antibodies in patients infected with the novel coronavirus","protected":false},"author":475,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1651],"tags":[232,260],"coauthors":[785],"class_list":["post-382299","post","type-post","status-publish","format-standard","hentry","category-notes","tag-pharmacology","tag-public-health","keywords-coronavirus-en","keywords-covid-19-en","keywords-sars-cov-2-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/382299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/users\/475"}],"replies":[{"embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/comments?post=382299"}],"version-history":[{"count":1,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/382299\/revisions"}],"predecessor-version":[{"id":382312,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/382299\/revisions\/382312"}],"wp:attachment":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/media?parent=382299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/categories?post=382299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/tags?post=382299"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/coauthors?post=382299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}